Barclays PLC decreased its stake in shares of Dynatrace, Inc. (NYSE:DT – Get Rating) by 77.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 474,998 shares of the company’s stock after selling 1,634,102 shares during the period. Barclays PLC’s holdings in Dynatrace were worth $16,534,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Ellevest Inc. bought a new stake in Dynatrace during the 3rd quarter valued at about $67,000. Los Angeles Capital Management LLC increased its position in Dynatrace by 49.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 792,228 shares of the company’s stock valued at $27,577,000 after purchasing an additional 261,025 shares during the period. Victory Capital Management Inc. increased its position in Dynatrace by 9.2% during the 3rd quarter. Victory Capital Management Inc. now owns 681,153 shares of the company’s stock valued at $23,710,000 after purchasing an additional 57,435 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in Dynatrace during the 3rd quarter valued at about $2,044,000. Finally, Crossmark Global Holdings Inc. purchased a new position in Dynatrace during the 3rd quarter valued at about $537,000. Institutional investors own 97.17% of the company’s stock.
Dynatrace Stock Down 2.7 %
NYSE:DT opened at $36.98 on Wednesday. The company has a market cap of $10.64 billion, a PE ratio of 369.84, a P/E/G ratio of 5.06 and a beta of 1.18. Dynatrace, Inc. has a twelve month low of $29.41 and a twelve month high of $56.98. The company has a current ratio of 1.20, a quick ratio of 1.20 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $37.50 and its two-hundred day moving average is $37.32.
Insider Buying and Selling at Dynatrace
In other Dynatrace news, CAO Alicia Allen sold 31,985 shares of Dynatrace stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $39.77, for a total transaction of $1,272,043.45. Following the completion of the sale, the chief accounting officer now directly owns 87,281 shares in the company, valued at approximately $3,471,165.37. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.51% of the company’s stock.
Analysts Set New Price Targets
DT has been the topic of a number of research reports. Barclays downgraded shares of Dynatrace from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $42.00 to $39.00 in a research report on Tuesday, January 10th. Robert W. Baird cut their target price on shares of Dynatrace from $49.00 to $40.00 in a research report on Thursday, November 3rd. The Goldman Sachs Group cut their target price on shares of Dynatrace from $61.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, November 3rd. JPMorgan Chase & Co. initiated coverage on shares of Dynatrace in a research report on Monday, October 3rd. They set an “overweight” rating on the stock. Finally, Royal Bank of Canada cut their target price on shares of Dynatrace from $41.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Dynatrace currently has an average rating of “Moderate Buy” and a consensus price target of $45.63.
Dynatrace, Inc provides a software intelligence platform for dynamic multi-cloud environments. It operates Dynatrace, a software intelligence platform, which provides application and microservices monitoring, runtime application security, infrastructure monitoring, digital experience monitoring, business analytics, and cloud automation.
- Get a free copy of the StockNews.com research report on Dynatrace (DT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Dynatrace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatrace and related companies with MarketBeat.com's FREE daily email newsletter.